

## Repligen Corp. (RGEN)

Market Cap: \$10B

SEPTEMBER 12-13, 2023 | MID-ATLANTIC



## Management

Tony Hunt

President, Chief Executive Officer

Steven Chehames

Manager, Investor Relations

## **Roadshow Host**

Jacob Johnson, CFA

Research Analyst
Diagnostics and Life Science Tools
615-279-4355

Jacob.Johnson@stephens.com

Space will be limited. Meeting times and itinerary subject to change. To join the trip or to obtain more information, please contact your Stephens sales representative.

## About Repligen Corp.

Repligen is a leading provider of advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. RGEN's revenue is diversified across product categories (filtration, chromatography, protein A, analytics, etc.) and across biologic drug end markets (monoclonal antibodies, recombinant proteins, cell/gene therapy, vaccines, etc.).



INSTITUTIONAL EQUITIES & RESEARCH

stephens.com

f in 💆 800-643-9691

© 2023 STEPHENS INC. MEMBER NYSE, SIPC | 111 CENTER STREET, LITTLE ROCK, AR 72201

UNSUBSCRIBE EMAIL PREFERENCES VIEW ONLINE

This amouncement has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or set any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. The research analyst principally responsible for preparation of this amouncement has reserved compensation that is based on the information and the research analyst principally responsible for preparation of this amouncement state close that the state of the research produced to the state of the st